Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules

Figures & data

Table 1. The distribution of clinically characters during 0–1 week in irritable bowel syndrome with predominant diarrhea (IBS-D) patients after fecal microbiota transplantation therapy

No.	Age	Gender	Treatment	Anxiety	Depression	IBS-SSS	Stool classification	Quality of life	Anxiety	Depression	IBS-SSS	Stool classification	Quality of life
				Week 0					Week 1
1	69	Male	Control	20.5	20	280	6	53	20	22	260	6	52
7	59	Female	Control	20.5	21.5	220	6	40	15	22	220	6	40
10	65	Male	Control	17	20.5	320	6	40	14.5	21	300	6	40
12	48	Male	Control	14.5	20.5	320	7	42	13.5	19	300	6	41
13	38	Male	Control	23.5	22.5	300	6	56	24	20.5	340	6	55
17	43	Female	Control	28.5	25.5	340	7	50	29	24.5	320	7	50
18	50	Male	Control	14.5	20.5	220	6	32	13.5	19.5	220	6	33
19	42	Female	Control	18	25	260	7	48	17	22.5	240	7	48
21	40	Female	Control	16.5	23.5	300	7	36	16	24.5	280	7	37
2	42	Female	FMT	24.5	24	260	6	51	15	22.5	180	6	49
4	35	Male	FMT	15	21.5	260	7	48	11.5	18.5	200	5	37
5	39	Male	FMT	23	21.5	360	5	48	18	24.5	240	5	45
6	63	Male	FMT	16.5	27.5	260	6	28	13.5	20	220	5	28
9	47	Male	FMT	18.5	22	300	5	44	12	21	200	5	41
14	39	Female	FMT	17.5	22	320	6	40	12.5	18	240	5	40
15	36	Female	FMT	18	20.5	340	7	54	12	16.5	240	5	48
16	58	Male	FMT	15.5	20	220	6	38	14.5	19	180	3	35
20	40	Female	FMT	16.5	22	300	6	39	12.5	19.5	240	4	36

Table 2. The distribution of clinically characters during 4–12 week in IBS-D patients after fecal microbiota transplantation therapy

No.	Age	Gender	Treatment	Anxiety	Depression	IBS-SSS	Stool classification	Quality of life	Anxiety	Depression	IBS-SSS	Stool classification	Quality of life	Anxiety	Depression	IBS-SSS	Stool classification	Quality of life
				Week 4					Week 8					Week 12
1	69	Male	Control	13	23	260	6	48	17	22	200	6	42	12	20	200	6	38
7	59	Female	Control	16.5	24	180	5	36	14	20.5	220	5	34	13	21.5	200	6	36
10	65	Male	Control	13.5	16	300	6	38	13.5	17.5	230	5	39	13.5	22	280	5	29
12	48	Male	Control	12	22	280	6	40	12	23	300	5	38	13	25	300	6	37
13	38	Male	Control	21.5	20.5	320	6	52	20	22.5	300	6	48	18	25.5	300	6	48
17	43	Female	Control	28.5	27.5	320	7	42	28.5	22	300	7	32	28	20	300	7	34
18	50	Male	Control	12	15.5	240	5	28	15	17.5	260	6	30	16.5	18	260	6	30
19	42	Female	Control	16	23	280	6	34	17	24.5	220	7	29	15	28	240	7	34
21	40	Female	Control	15.5	23.5	280	6	38	13	22	280	7	36	16.5	22.5	280	7	35
2	42	Female	FMT	13.5	20	160	6	40	11	19.5	140	5	28	16	18.5	220	6	18
4	35	Male	FMT	2	13.5	180	5	22	5	13.5	160	4	14	4	13.5	160	4	4
5	39	Male	FMT	16	21.5	280	7	32	14	22.5	220	5	28	15.5	25.5	240	5	45
6	63	Male	FMT	10.5	18	160	6	21	10	17.5	140	5	26	8	18.5	160	5	22
9	47	Male	FMT	9.5	20	140	5	28	8	19	120	4	28	9	18	160	4	28
14	39	Female	FMT	9.5	18.5	160	5	28	8.5	18.5	140	5	27	9	18	200	5	28
15	36	Female	FMT	9.5	19	120	4	32	10	17.5	160	5	24	9	18	200	5	24
16	58	Male	FMT	3.5	21	120	3	24	3	16.5	100	3	26	3	18	120	3	18
20	40	Female	FMT	8	16	180	4	21	6	15.5	120	4	21	7.5	18.5	140	4	19

Figure 1. The heat map demonstration of dominant bacterial community response of different fecal microbiota transplantation (FMT) treated duration-based Phylum (a), Class (b), Order (c), Family (d), and Genus (e) level. The FMT capsuletreated irritable bowel syndrome with predominant diarrhea (IBS-D) patients 1 week (A1), 8 weeks (A2), and 12 weeks (A3), as well as control with oral empty capsules 1 week (B1), 8 weeks (B2), and 12 weeks (B3)

Figure 2. The dominant bacterial community under different fecal microbiota transplantation (FMT) treated duration at Phylum (a), Class (b), Order (c), Family (d), and Genus (e) level. The FMT capsuletreated IBS-D patients 1 week (A1), 8 weeks (A2), and 12 weeks (A3), as well as control with oral empty capsules 1 week (B1), 8 weeks (B2), and 12 weeks (B3)

Figure 3. Alpha diversity of bacterial community-based chao1 (a), observed _species (b), PD whole tree (c) and Shannon (d). The FMT capsules treated IBS-D patients 1 week (A1), 8 weeks (A2), and 12 weeks (A3), as well as control with oral empty capsules 1 week (B1), 8 weeks (B2), and 12 weeks (B3)

Figure 4. Beta diversity-based bacterial principal co-ordinates (a), nonmetric multidimensional scaling (b), and principal component analysis (c). The FMT capsule-treated IBS-D patients 1 week (A1), 8 weeks (A2), and 12 weeks (A3), as well as control with oral empty capsules 1 week (B1), 8 weeks (B2), and 12 weeks (B3)

Figure 5. The correlation of selected bacterial community-based network analysis